Cargando…

Continuous Increase of Efficacy under Repetitive Injections of Botulinum Toxin Type/A beyond the First Treatment for Adult Spastic Foot Drop

The objective of this study was to quantify the increase in efficacy during the first four cycles of treatment with botulinum toxin type/A (BoNT/A) in 24 free-walking BoNT/A naïve adult patients with post-stroke hemispasticity and spastic foot drop. Patients were followed over 390 days and received...

Descripción completa

Detalles Bibliográficos
Autores principales: Hefter, Harald, Nickels, Werner, Rosenthal, Dietmar, Samadzadeh, Sara, Albrecht, Philipp
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8310361/
https://www.ncbi.nlm.nih.gov/pubmed/34357938
http://dx.doi.org/10.3390/toxins13070466
_version_ 1783728743259308032
author Hefter, Harald
Nickels, Werner
Rosenthal, Dietmar
Samadzadeh, Sara
Albrecht, Philipp
author_facet Hefter, Harald
Nickels, Werner
Rosenthal, Dietmar
Samadzadeh, Sara
Albrecht, Philipp
author_sort Hefter, Harald
collection PubMed
description The objective of this study was to quantify the increase in efficacy during the first four cycles of treatment with botulinum toxin type/A (BoNT/A) in 24 free-walking BoNT/A naïve adult patients with post-stroke hemispasticity and spastic foot drop. Patients were followed over 390 days and received five injections of 800 U aboBoNT/A every three months. Patients assessed the treatment effect at eight visits using a global assessment scale, physicians scored the muscle tone at the ankle joint, measured active and passive ranges of motion (aRoMs, pRoMs) at the knee and ankle joint and determined the distance patients succeeded to walk during a minute. Patients’ assessments significantly (p < 0.006) increased with time and significantly correlated with all parameters measured. The best correlation (r = 0.927; p < 0.0001) was found with the sum of the aRoMs of knee and ankle joint. After one year of treatment outcome measures were better than and significantly correlated with the peak effect of the first injection. This correlation was higher for pRoMs (r = 0.855; p < 0.00001) compared to aRoMs (r = 0.567; p < 0.009). When BoNT/A treatment of the spastic foot in chronic hemispasticity is performed regularly every three months for at least one year, patients will experience a significant increase of benefit beyond the first treatment, but have to learn how to adapt to and use the new degree of freedom induced by the injections.
format Online
Article
Text
id pubmed-8310361
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-83103612021-07-25 Continuous Increase of Efficacy under Repetitive Injections of Botulinum Toxin Type/A beyond the First Treatment for Adult Spastic Foot Drop Hefter, Harald Nickels, Werner Rosenthal, Dietmar Samadzadeh, Sara Albrecht, Philipp Toxins (Basel) Article The objective of this study was to quantify the increase in efficacy during the first four cycles of treatment with botulinum toxin type/A (BoNT/A) in 24 free-walking BoNT/A naïve adult patients with post-stroke hemispasticity and spastic foot drop. Patients were followed over 390 days and received five injections of 800 U aboBoNT/A every three months. Patients assessed the treatment effect at eight visits using a global assessment scale, physicians scored the muscle tone at the ankle joint, measured active and passive ranges of motion (aRoMs, pRoMs) at the knee and ankle joint and determined the distance patients succeeded to walk during a minute. Patients’ assessments significantly (p < 0.006) increased with time and significantly correlated with all parameters measured. The best correlation (r = 0.927; p < 0.0001) was found with the sum of the aRoMs of knee and ankle joint. After one year of treatment outcome measures were better than and significantly correlated with the peak effect of the first injection. This correlation was higher for pRoMs (r = 0.855; p < 0.00001) compared to aRoMs (r = 0.567; p < 0.009). When BoNT/A treatment of the spastic foot in chronic hemispasticity is performed regularly every three months for at least one year, patients will experience a significant increase of benefit beyond the first treatment, but have to learn how to adapt to and use the new degree of freedom induced by the injections. MDPI 2021-07-02 /pmc/articles/PMC8310361/ /pubmed/34357938 http://dx.doi.org/10.3390/toxins13070466 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Hefter, Harald
Nickels, Werner
Rosenthal, Dietmar
Samadzadeh, Sara
Albrecht, Philipp
Continuous Increase of Efficacy under Repetitive Injections of Botulinum Toxin Type/A beyond the First Treatment for Adult Spastic Foot Drop
title Continuous Increase of Efficacy under Repetitive Injections of Botulinum Toxin Type/A beyond the First Treatment for Adult Spastic Foot Drop
title_full Continuous Increase of Efficacy under Repetitive Injections of Botulinum Toxin Type/A beyond the First Treatment for Adult Spastic Foot Drop
title_fullStr Continuous Increase of Efficacy under Repetitive Injections of Botulinum Toxin Type/A beyond the First Treatment for Adult Spastic Foot Drop
title_full_unstemmed Continuous Increase of Efficacy under Repetitive Injections of Botulinum Toxin Type/A beyond the First Treatment for Adult Spastic Foot Drop
title_short Continuous Increase of Efficacy under Repetitive Injections of Botulinum Toxin Type/A beyond the First Treatment for Adult Spastic Foot Drop
title_sort continuous increase of efficacy under repetitive injections of botulinum toxin type/a beyond the first treatment for adult spastic foot drop
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8310361/
https://www.ncbi.nlm.nih.gov/pubmed/34357938
http://dx.doi.org/10.3390/toxins13070466
work_keys_str_mv AT hefterharald continuousincreaseofefficacyunderrepetitiveinjectionsofbotulinumtoxintypeabeyondthefirsttreatmentforadultspasticfootdrop
AT nickelswerner continuousincreaseofefficacyunderrepetitiveinjectionsofbotulinumtoxintypeabeyondthefirsttreatmentforadultspasticfootdrop
AT rosenthaldietmar continuousincreaseofefficacyunderrepetitiveinjectionsofbotulinumtoxintypeabeyondthefirsttreatmentforadultspasticfootdrop
AT samadzadehsara continuousincreaseofefficacyunderrepetitiveinjectionsofbotulinumtoxintypeabeyondthefirsttreatmentforadultspasticfootdrop
AT albrechtphilipp continuousincreaseofefficacyunderrepetitiveinjectionsofbotulinumtoxintypeabeyondthefirsttreatmentforadultspasticfootdrop